Is lamivudine with 1-week hblg as effective as long-term high-dose hblg in hbv prophylaxis after liver transplantation?

Park, S.-J; Paik, Seung Woon; Choi, Moon Seok; Lee, J.H; Koh, Kwang Cheol; Kim, S.J; Joh, Jae‐Won; Lee, S.K

doi:10.1016/s0041-1345(02)02637-4

Cited by 21 publications

(20 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…None of the compliant patients developed HBV recurrence. Our data are consistent with earlier published reports where the duration of follow‐up after HBIG withdrawal was shorter than in our study 26–28, 33. Dodson et al26 prospectively followed 16 patients who were switched to LAM monotherapy after 24 months of IV HBIG.…”

Section: Discussionsupporting

confidence: 93%

“…HBV recurrence occurred in 2 of 12 patients in the LAM group; both had received <12 months of HBIG before being switched to LAM monoprophylaxis 27. Two other studies used relatively short durations of LAM and HBIG combination therapy (1‐4 weeks) followed by LAM monotherapy, with HBV recurrence rates of 0‐10% at 18 months after OLT 28, 33. Two reports published as abstracts showed higher rates of recurrence after longer follow‐up.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Low risk of hepatitis B virus recurrence after withdrawal of long-term hepatitis B immunoglobulin in patients receiving maintenance nucleos(t)ide analogue therapy

et al. 2007

View full text Add to dashboard Cite

Hepatitis B virus (HBV) recurrence rates of 0-16% had been reported in patients maintained on nucleoside analogues (NA) after hepatitis B immunoglobulin (HBIG) discontinuation after orthotopic liver transplantation (OLT). However, follow-up in most studies was short. We aimed to determine the long-term risk of HBV recurrence using this strategy. All HBV patients who received Ն7 doses of intravenous HBIG after OLT, with no HBV recurrence while receiving HBIG, and who eventually discontinued HBIG and were maintained on NA, were included. HBV recurrence was defined as HBsAg-positive or HBV DNA Ն5 log copies/mL on 2 consecutive occasions. Twenty-one patients met the inclusion criteria. Immediate post-OLT prophylaxis was combination HBIG and NA in 15 patients, whereas 6 patients received HBIG monotherapy for 62-109 months before NA was added. HBIG was discontinued a median of 26 (range, 0.2-121) months after OLT. Median follow-up post-HBIG discontinuation was 40 (range, 5-51) months. Only 1 patient, who had 12 months of HBIG and was noncompliant to NA therapy, had HBV recurrence, 34 months after HBIG discontinuation. One patient had HBV DNA of 3.3 log copies/mL 47 and 48 months after HBIG discontinuation but remained HBsAg-negative. Lamivudine-resistant mutations were detected in both patients. Probability of HBV recurrence was 0% and 9% at 2 and 4 years after HBIG discontinuation. Three patients had 1-2 episodes of transiently detectable HBV DNA. All were HBV DNA and HBsAg negative on repeated tests over a period of 2-36 months. Maintenance therapy with NA after discontinuation of long-term HBIG therapy is associated with a low risk of HBV recurrence after OLT in compliant HBV patients. Liver Transpl 13: [374][375][376][377][378][379][380][381] 2007. © 2007 AASLD.Received June 29, 2006; accepted October 18, 2006. Before the advent of antiviral prophylaxis, the prognosis of patients undergoing orthotopic liver transplantation (OLT) for hepatitis B virus (HBV)-related liver disease was poor because of the high (80-100%) rate of graft reinfection after OLT.1,2 Recurrence of hepatitis B in liver transplant recipients generally follows a more aggressive course than in immunocompetent patients, with a 2-year mortality of 50%. Fortunately, tremendous strides in antiviral prophylactic measures have been made in the last 20 years. 3 The administration of either high-dose intravenous (IV) hepatitis B immunoglobulin (HBIG) or lamivudine (LAM) for an indefinite duration after OLT have resulted in a marked reduction in 3-year HBV recurrence rates to 15-25% for HBIG [4][5][6] and 20-40% for LAM monotherapy. [7][8][9] In recent years, the combination of IV HBIG and LAM resulted in further reduction in HBV recurrence rates to less than 10% up to 3 years after OLT. 6,[10][11][12][13]

show abstract

Section: Discussionsupporting

confidence: 93%

Section: Discussionmentioning

confidence: 99%

Low risk of hepatitis B virus recurrence after withdrawal of long-term hepatitis B immunoglobulin in patients receiving maintenance nucleos(t)ide analogue therapy

et al. 2007

View full text Add to dashboard Cite

show abstract

“…During the last decades, efforts to reduce the duration of HBIG administration to decrease the costs have been made. Several studies have successfully attempted to limit dose and duration of HBIG administration . In a study where patients were randomized to either lamivudine monotherapy or in combination with HBIG 1 month after LT, no HBV recurrence occurred at 18 months .…”

Section: Discussionmentioning

confidence: 99%

Shorter hepatitis B immunoglobulin administration is not associated to hepatitis B virus recurrence when receiving combined prophylaxis after liver transplantation

Lens

García‐Eliz

Fernández

et al. 2018

Liver International

View full text Add to dashboard Cite

show abstract

“…Lastly, Nath suggested that LAM/ADV combination prophylactic therapy would be a viable option for managing HBV post-transplant patients [24]. The last two studies we reviewed used very-short HBIG duration with LAM after HBIG withdrawal (see Table 4 for HBV recurrence results) [25][26][27].…”

Section: Very Short-term Hbig (1 Month or Less)mentioning

confidence: 99%

Efficacy and effectiveness of anti-HBV therapy with early withdrawal of HBIG prophylaxis to prevent HBV recurrence following liver transplantation

Wang

Nguyen

2015

Expert Opinion on Biological Therapy

View full text Add to dashboard Cite

show abstract

Is lamivudine with 1-week hblg as effective as long-term high-dose hblg in hbv prophylaxis after liver transplantation?

Cited by 21 publications

References 7 publications

Low risk of hepatitis B virus recurrence after withdrawal of long-term hepatitis B immunoglobulin in patients receiving maintenance nucleos(t)ide analogue therapy

Low risk of hepatitis B virus recurrence after withdrawal of long-term hepatitis B immunoglobulin in patients receiving maintenance nucleos(t)ide analogue therapy

Shorter hepatitis B immunoglobulin administration is not associated to hepatitis B virus recurrence when receiving combined prophylaxis after liver transplantation

Efficacy and effectiveness of anti-HBV therapy with early withdrawal of HBIG prophylaxis to prevent HBV recurrence following liver transplantation

Contact Info

Product

Resources

About